- Home
- MIRM vs PET Comparison
MIRM vs PET Comparison
Compare MIRM & PET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- PET
- Stock Information
- Founded
- MIRM 2018
- PET 2015
- Country
- MIRM United States
- PET United States
- Employees
- MIRM N/A
- PET N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- PET EDP Services
- Sector
- MIRM Health Care
- PET Technology
- Exchange
- MIRM Nasdaq
- PET Nasdaq
- Market Cap
- MIRM 1.9B
- PET N/A
- IPO Year
- MIRM 2019
- PET N/A
- Fundamental
- Price
- MIRM $39.10
- PET $0.11
- Analyst Decision
- MIRM Strong Buy
- PET Strong Buy
- Analyst Count
- MIRM 11
- PET 5
- Target Price
- MIRM $58.55
- PET $4.90
- AVG Volume (30 Days)
- MIRM 476.2K
- PET 539.7K
- Earning Date
- MIRM 05-07-2025
- PET 05-08-2025
- Dividend Yield
- MIRM N/A
- PET N/A
- EPS Growth
- MIRM N/A
- PET N/A
- EPS
- MIRM N/A
- PET N/A
- Revenue
- MIRM $336,888,000.00
- PET $70,507,000.00
- Revenue This Year
- MIRM $29.51
- PET $7.87
- Revenue Next Year
- MIRM $20.27
- PET $122.23
- P/E Ratio
- MIRM N/A
- PET N/A
- Revenue Growth
- MIRM 80.76
- PET N/A
- 52 Week Low
- MIRM $23.14
- PET $0.10
- 52 Week High
- MIRM $54.23
- PET $2.47
- Technical
- Relative Strength Index (RSI)
- MIRM 34.64
- PET 31.40
- Support Level
- MIRM $37.83
- PET $0.10
- Resistance Level
- MIRM $40.32
- PET $0.14
- Average True Range (ATR)
- MIRM 2.47
- PET 0.03
- MACD
- MIRM -0.33
- PET 0.00
- Stochastic Oscillator
- MIRM 25.14
- PET 14.29
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.